Eloxx Pharmaceuticals, Inc. (ELOX) Q4 2020 Earnings Call

Investor webinar replay

Replay transcript excerpt

webcast and conference call. Today's call is being recorded. At this time, I would like to turn the call over to Barbara Ryan, ELOX Investor Relations. Please begin. Thank you, Victor. Welcome and thank you for joining us this afternoon for a review of ELOX Pharmaceutical's fourth quarter and full year 2020 financial results and business update. Joining me this afternoon are Dr. Greg Williams, our Chief Executive Officer, Neil Beloff, Chief Operating Officer and General Counsel, Dr. Tom Haverty, our Chief Medical Officer, Dr. Matthew Guderis, Vice President of Research, and Stephen McDonald, our Vice President of Finance and Accounting. Before we begin, I would like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the risk factors section in our most recent annual report on Form 10-K, filed with the Securities and Exchange Commission, as well as our other reports filed with the SEC. Any forward-looking statements represent our views as of today, March 11, 2021 only. A replay of this call will be available on the company's website, www.eloxpharma.com, following the call. It is now my great pleasure to turn the call over to Dr. Greg Williams, Chief Executive Officer of Elox Pharmaceuticals. Thank you, Barbara, and welcome to Elox's fourth quarter and full-year 2020 earnings webcast and conference call. We are continuing to advance our clinical and scientific programs for our ERSG library. Our highest priority is to complete our phase two clinical trials for ELXO2 in cyst...